Zobrazeno 1 - 10
of 10
pro vyhledávání: '"David Floch"'
Autor:
Benjamin A Fisher, Michele Bombardieri, Hans-Ulrich Hockey, Antónia Szántó, Andrew M Wright, Athena Papas, Michael Rotte, Alexandre Avrameas, David A. Isenberg, Bettina Bannert, Pascal Espie, Cyrielle Dupuy, Steven E. Carsons, Diego Kyburz, Maximilian G. Posch, Marie-Anne Valentin, Julie Milojevic, Francesca Barone, Petra M Faerber, Simon J Bowman, Arwa M. Farag, Thomas Daikeler, Xiaohui Ren, Peter Gergely, David Floch, Wan-Fai Ng, James S. Rush, Alan Kivitz
Publikováno v:
The Lancet Rheumatology. 2:e142-e152
Summary Background Primary Sjogren's syndrome is an autoimmune disease that presents as dryness of the mouth and eyes due to impairment of the exocrine glands. To our knowledge, no systemic therapies for primary Sjogren's syndrome have shown efficacy
Autor:
Peter Gergely, Pascal Espie, Michele Bombardieri, Bettina Bannert, Pierre Moulin, Athena Papas, Maximilian G. Posch, Michael Rotte, Benjamin A Fisher, Simon J. Bowman, Arwa M. Farag, Amanda Nguyen, David Floch, James S. Rush, Wan-Fai Ng, Andrew M Wright, Grazyna Wieczorek, Cyrielle Dupuy, Alan Kivitz, Francesca Barone, Steven E. Carsons, Antónia Szántó, David A. Isenberg, Thomas Daikeler
Publikováno v:
Poster Presentations.
Background: Primary Sjogren’s syndrome (pSS) is a systemic progressive autoimmune disease characterised by formation of lymphoid structures and germinal centres within glandular tissue. Iscalimab (CFZ533) is a novel monoclonal antibody that potentl
Autor:
Ulf R. Klein, Linh M. Van, Xuemin Jiang, David Floch, Ken Abrams, Gangadhar Sunkara, Haiying Sun
Publikováno v:
The Journal of Clinical Pharmacology. 56:1516-1527
The pharmacokinetics and pharmacodynamic (PD) properties of a monoclonal antibody, canakinumab, in pediatric patients with systemic juvenile idiopathic arthritis are presented. Blood samples were obtained from 4 phase II/III clinical studies in patie
Autor:
Haiying Sun, Christine Reynolds, Sam Lindgren, Hans-Joachim Wallny, SivaNaga S. Anumolu, Janardhana Vemula, David Floch
Publikováno v:
Clinical pharmacology in drug development. 7(8)
Canakinumab, a high-affinity human anti-interleukin-1β monoclonal antibody, is being used for the treatment of a broad spectrum of inflammatory diseases. This phase 1 study compared the relative bioavailability of a single dose of subcutaneous canak
Autor:
Ieuan Jones, Andrej Skerjanec, S. Maahs, Ivan Bottoli, Philip J. Lowe, David Floch, Jonathan P. Arm, C. E. Owen, Andrea Groenewegen
Publikováno v:
Clinical and Experimental Allergy
SummaryBackground Using a monoclonal antibody with greater affinity for IgE than omalizumab, we examined whether more complete suppression of IgE provided greater pharmacodynamic effects, including suppression of skin prick responses to allergen. Obj
Autor:
Alan Kivitz, Xiaohui Ren, Steven E. Carsons, Michele Bombardieri, Pierre Moulin, Wan-Fai Ng, Arwa M. Farag, James S. Rush, Peter Gergely, David A. Isenberg, Bettina Bannert, Margit Zeher, Pascal Espie, Thomas Daikeler, Petra M Faerber, Athena Papas, Francesca Barone, Andrew M Wright, Michael Rotte, Benjamin A Fisher, Hans Ulrich Hockey, Simon J. Bowman, Grazyna Wieczorek, Maximilian G. Posch, David Floch, Cyrielle Dupuy
Publikováno v:
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 126:e203-e204
Autor:
Abhijit Chakraborty, Linh M. Van, Gangadhar Sunkara, Gerhard Krammer, Andrej Skerjanec, David Floch, Ulf R. Klein, Dan Howard
Publikováno v:
The Journal of Clinical Pharmacology. 53:1240-1251
Pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1β monoclonal antibody, canakinumab, in gouty arthritis patients from three studies are reported. Canakinumab has low serum clearance (0.214 L/day), low steady-state volume of distri
Autor:
Haiying, Sun, Linh M, Van, David, Floch, Xuemin, Jiang, Ulf R, Klein, Ken, Abrams, Gangadhar, Sunkara
Publikováno v:
Journal of clinical pharmacology. 56(12)
The characterization of the pharmacokinetic (PK) and pharmacodynamic (PD) properties in pediatric patients is essential in supporting the recommended dosage of canakinumab in the relevant population. Here the PK and PD properties of canakinumab-a mon
Autor:
Abhijit, Chakraborty, Linh M, Van, Andrej, Skerjanec, David, Floch, Ulf R, Klein, Gerhard, Krammer, Gangadhar, Sunkara, Dan, Howard
Publikováno v:
Journal of clinical pharmacology. 53(12)
Pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1β monoclonal antibody, canakinumab, in gouty arthritis patients from three studies are reported. Canakinumab has low serum clearance (0.214 L/day), low steady-state volume of distri
Autor:
Philip J. Lowe, David Floch, Abhijit Chakraborty, Christiane Rordorf, Stacey Tannenbaum, Sandip Roy, Hermann Gram
Publikováno v:
Clinical Pharmacokinetics
Canakinumab is a high-affinity human monoclonal anti-interleukin-1β (IL-1β) antibody of the IgG1/κ isotype designed to bind and neutralize the activity of human IL-1β, a pro-inflammatory cytokine. Canakinumab is currently being investigated on th